Comparison · NCT00260832-sae
Cytarabine or Supportive Care vs Dacogen (Decitabine) Only: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cytarabine or Supportive Care vs Dacogen (Decitabine) Only: serious adverse events. Trial comparisons, record NCT00260832-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00260832-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.684 | 0.622 | 0.739 | wilson | |
| Risk in group 2 | 0.798 | 0.743 | 0.844 | wilson | |
| Risk difference, group 1 minus group 2 | -0.115 | -0.192 | -0.036 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.856 | 0.769 | 0.954 | log | |
| Odds ratio, group 1 over group 2 | 0.546 | 0.359 | 0.829 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Cytarabine or Supportive Care than on Dacogen (Decitabine) Only | 8.71 | 5.21 | 27.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cytarabine or Supportive Care | Subject's choice of treatment with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m\^2 given subcutaneously once daily for 10 consecutive days, repeated every 4 weeks. (These represent one intervention.) | 162 | 237 | EG000 |
| Group 2 | Dacogen (Decitabine) Only | 20 mg/m\^2 Dacogen (decitabine) given as 1-hour infusion once daily for 5 consecutive days every 4 weeks. | 190 | 238 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Trial of Decitabine in Patients With Acute Myeloid Leukemia
- NCT number
- NCT00260832
- Phases
- PHASE3
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Cytarabine or Supportive Care, Dacogen (decitabine) only
- Lead sponsor
- Eisai Inc.
- Results first posted
- 2011-09-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00260832?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00260832-sae